Inventor
LEDERMAN SETH
US34 patents
⚠️ This page may combine multiple inventors who share the name “LEDERMAN SETH”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV COLUMBIA
13 patentsUS5474771ADec 12, 1995
Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
UNIV COLUMBIA152 citations98
US5756710AMay 26, 1998
Phosphorothioate oligonucleotides that bind to the V3-loop and uses thereof
UNIV COLUMBIA147 citations97
US6793924B2Sep 21, 2004
Protein recognized by an antibody that specifically binds an epitope that is specifically bound by monoclonal antibody 5c8.
UNIV COLUMBIA31 citations96
US6610294B1Aug 26, 2003
Methods of inhibiting an autoimmune response in a human suffering from an autoimmune disease by administering an antibody that binds to a protein to which monoclonal antibody 5C8 binds
UNIV COLUMBIA36 citations96
US6592868B1Jul 15, 2003
Methods for treating autoimmune diseases with 5C8-specific antibodies
UNIV COLUMBIA33 citations96
US6455044B1Sep 24, 2002
5c8 antigen
UNIV COLUMBIA33 citations96
US6451310B1Sep 17, 2002
Method for inhibiting an allergic response with a 5c8-specific antibody
UNIV COLUMBIA41 citations96
US6403091B1Jun 11, 2002
Methods for inhibiting the rejection of a transplant organ in a subject with 5C8-specific antibodies
UNIV COLUMBIA42 citations96
US6340459B1Jan 22, 2002
Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
UNIV COLUMBIA53 citations96
US7070777B1Jul 4, 2006
Method for inhibiting inflammation with an antibody that binds the 5C8 protein
UNIV COLUMBIA15 citations84
US6331615B1Dec 18, 2001
Nucleic acid molecule encoding heavy or light chain of an antibody which specifically recognizes a protein specifically recognized by monoclonal antibody 5c8 (anti-CD40 ligand)
UNIV COLUMBIA10 citations82
US6331433B1Dec 18, 2001
Human T cell leukemia cell line designated D1.1
UNIV COLUMBIA10 citations82
US6849415B2Feb 1, 2005
TRAF-3 deletion isoforms and uses thereof
UNIV COLUMBIA0 citations44
TONIX PHARMA HOLDINGS LTD
5 patentsUS10357465B2Jul 23, 2019
Eutectic formulations of cyclobenzaprine hydrochloride
TONIX PHARMA HOLDINGS LTD14 citations93
US11026898B2Jun 8, 2021
Eutectic formulations of cyclobenzaprine hydrochloride
TONIX PHARMA HOLDINGS LTD6 citations83
US9474728B2Oct 25, 2016
Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
TONIX PHARMA HOLDINGS LTD15 citations79
US10722478B2Jul 28, 2020
Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
TONIX PHARMA HOLDINGS LTD2 citations68
US11826321B2Nov 28, 2023
Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
TONIX PHARMA HOLDINGS LTD1 citations61
LEDERMAN SETH
4 patentsUS8093300B2Jan 10, 2012
Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
LEDERMAN SETH18 citations92
US9918948B2Mar 20, 2018
Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
LEDERMAN SETH12 citations79
US11998516B2Jun 4, 2024
Methods and compositions for treating depression using cyclobenzaprine
LEDERMAN SETH0 citations62
US8481599B2Jul 9, 2013
Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
LEDERMAN SETH0 citations51